Home / Executive Moves / Former SC3 CFO Charles Hicks Joins NCI as Finance Chief; Paul Dillahay Quoted

Former SC3 CFO Charles Hicks Joins NCI as Finance Chief; Paul Dillahay Quoted

Jeff Brody
Charles Hicks

Charles Hicks, former chief operating officer and chief financial officer of SC3, has joined NCI Information Systems as executive vice president, CFO and corporate treasurer.

“Chuck is a well-known change agent and a highly respected finance/business leader in the GovCon market,” Paul Dillahay, president and CEO of NCI and a former Wash100 Award winner, said in a statement released Tuesday.

“He has a stellar track record of driving financial operational excellence and will be integral in helping shape our decision making as we continue to execute on our growth strategy,” Dillahay added. 

Hicks brings over 25 years of experience in merger and acquisition transactions, integration initiatives to improve operational excellence, efficiency and performance and strategic partnerships to his new role.

Prior to NCI, he held a similar position at commercial real estate company Cresa Global and also worked at ASRC Federal, Science Applications International Corp. (NYSE: SAIC), USIS and Ernst & Young.

He served in the U.S. Navy for six years before joining the private sector.

“This is an exciting time for our company, as we partner with our federal customers to help advance their mission utilizing emerging technologies and innovative solutions such as artificial intelligence, advanced data analytics and agile software development,” Hicks said.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.